Form 4 for KALA KALA BIO, Inc.
Accepted 2022-10-28 00:00:00 ET · period of report 2022-10-26 · accession 0001415889-22-010880 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-10-28 | 2022-10-26 | KALA | Reumuth Mary | CFO | S - Sale | $6.51 | -194 | 2,418 | -7% | -$1,263 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-26 | S | D | 194 | $6.51 | 2,418 | D | — | — | (F1) This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020. (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.56, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. (F3) Includes 302 unvested RSUs. (F4) The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. |